Burning mouth syndrome: Difference between revisions

From IDWiki
(Created page with "* Syndrome of chronic oral pain * Mostly affects perimenopausal or postmenopaulsa women * Pathophysiology thought to be neuropathic * Pain is characterized as burning of oral mucosa, and may have associated dysgeusia, paresthesia, dysesthesia, and xerostomia * Treatments include alpha-lipoic acid (ALA) supplementation, topical clonazepam, gabapentin, combination ALA and gabapentin, Catauma, or bupivacaine")
 
No edit summary
 
Line 3: Line 3:
 
* Pathophysiology thought to be neuropathic
 
* Pathophysiology thought to be neuropathic
 
* Pain is characterized as burning of oral mucosa, and may have associated dysgeusia, paresthesia, dysesthesia, and xerostomia
 
* Pain is characterized as burning of oral mucosa, and may have associated dysgeusia, paresthesia, dysesthesia, and xerostomia
* Treatments include [[alpha-lipoic acid]] (ALA) supplementation, topical [[clonazepam]], [[gabapentin]], combination [[ALA]] and [[gabapentin]], [[Catauma]], or [[bupivacaine]]
+
* Treatments include [[alpha-lipoic acid]] (ALA) supplementation, topical [[clonazepam]], [[gabapentin]], combination [[ALA]] and [[gabapentin]], [[Catauma]], or [[bupivacaine]]<ref>Liu YF, Kim Y, Yoo T, Han P, Inman JC. Burning mouth syndrome: a systematic review of treatments. Oral Dis. 2018 Apr;24(3):325-334. doi: [https://doi.org/10.1111/odi.12660 10.1111/odi.12660]. Epub 2017 Mar 30. PMID: [https://pubmed.ncbi.nlm.nih.gov/28247977/ 28247977].</ref>

Latest revision as of 14:26, 26 September 2022

  • Syndrome of chronic oral pain
  • Mostly affects perimenopausal or postmenopaulsa women
  • Pathophysiology thought to be neuropathic
  • Pain is characterized as burning of oral mucosa, and may have associated dysgeusia, paresthesia, dysesthesia, and xerostomia
  • Treatments include alpha-lipoic acid (ALA) supplementation, topical clonazepam, gabapentin, combination ALA and gabapentin, Catauma, or bupivacaine[1]
  1. Liu YF, Kim Y, Yoo T, Han P, Inman JC. Burning mouth syndrome: a systematic review of treatments. Oral Dis. 2018 Apr;24(3):325-334. doi: 10.1111/odi.12660. Epub 2017 Mar 30. PMID: 28247977.